The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Antagomir for cutaneous T-cell lymphoma: promising trial results
In cutaneous T-cell lymphoma (CTCL) miR-155 has been shown to be upregulated. Here, Christiane Querfeld, MD, PhD, of City of Hope, Duarte, CA, discusses an antogomir being developed to target this variance. MRG-106, an inhibitor of miR-155, is in Phase I trials (NCT02580552) in patients with CTCL, in addition to other lymphoid malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Querfeld discusses the initial results and progression of this study.
